prvi bosansko-hercegovački i drugi jadranski kongres ...

Evaluation of utilization of old versus newer antiepileptic drugs in Republic
of Macedonia
Bojana Danilovska, Zoran Sterjev, Ljubica Suturkova
ISPOR –Skopje, regional ISPOR chapter from
Republic of Macedonia, Skopje, Macedonia
Goal: New, ‘second generation’ antiepileptic
drugs (AEDs) which have entered the marketplace
since 1990 are currently taken by approximately
16% of patients with epilepsy worldwide.
Concerning the efficacy of these drugs in comparison
to the older ones, they are generally
considered to have equal efficacy. In some conditions
are slightly more efficacious but the differences
in price are still very big. In the present
study we evaluated and compared utilization and
cost of “old” and “newer AEDs” which are present
in reimbursement drug list in R.Macedonia,
for the period 2009-2010.
Materials and methods: We used official data obtained
from Health Insurance Found of Republic
of Macedonia (FZO) and defined daily dose
Proofreading and translations are in the explicit responsibility of the authors.
P 05
(DDD), as a method for drug use evaluation,
defined by WHO Collaborating Centre for Drug
Statistics Methodology.
Results: Carbamazpine (CBZ) was commonly
prescribed antiepileptic drug in comparison with
other AEDs (0,00053DDD/1000 people per day
in 2009 and 0,00074 DDD/1000 people per day
in 2010). The FZO cost for AEDs 2009 v.s. 2010
was: 268915 v.s. 278257 euros for CBZ, 314821
v.s. 365101euros for Valproic acid (VAL), 116433
v.s. 100361 euros for Lamotrigine and 313522 v.s.
184875 euros for Topiramate.
Conclusion: The trend of utilization of the standard
AEDs in Macedonia showed that the old
AEDs are stiil therapy of choice for treatment of
epilepsy.
51